[The role of the progesterone antagonist, RU 486 (mifepristone), in preoperative cervical dilatation during the luteal phase. A randomized double-blind study].
Fernandez
H
H
Durlot
F
F
Dubois
C
C
Ulmann
A
A
Frydman
R
R
D001695:Biology; D002584:Cervix Uteri; D019049:Developed Countries; D003933:Diagnosis; D004311:Double-Blind Method; D004703:Endocrine System; D004724:Endoscopy; D005060:Europe; D005602:France; D005835:Genitalia; D005836:Genitalia, Female; D006727:Hormone Antagonists; D006728:Hormones; D015907:Hysteroscopy; D007747:Labor Stage, First; D015735:Mifepristone; D010808:Physical Examination; D010827:Physiology; D012106:Research; D013812:Therapeutics; D014566:Urogenital System; D014599:Uterus
D006727:Hormone Antagonists; D006728:Hormones; D015735:Mifepristone
Biology; Cervical Dilatation; Cervical Effects; Cervix; Developed Countries; Double-blind Studies; Endocrine System; Endoscopy; Europe; Examinations And Diagnoses; France; Genitalia; Genitalia, Female; Hormone Antagonists; Hormones; Hysteroscopy; Mediterranean Countries; Physical Examinations And Diagnoses; Physiology; Research Methodology; Ru-486--administraction and dosage; Studies; Treatment; Urogenital System; Uterus; Western Europe